Virtually all cancers have aberrant signaling of receptor tyrosine kinases (RTKs), growth factors autocrine loops or activating mutations in the RAS pathway (RAS activating mutations or BRAFV600E mutation). This evidence concerns the gene NTRK1 and cancer.